Bandle Brian, Ward Kelsey, Min Sung-Joon, Drake Cynthia, McIlvennan Colleen K, Kao David, Wald Heidi L
New York Department of Public Health, Albany, New York.
University of Colorado School of Medicine, Aurora, Colorado.
J Am Geriatr Soc. 2017 Jun;65(6):1328-1332. doi: 10.1111/jgs.14801. Epub 2017 Feb 21.
Braden score is a routine assessment of pressure ulcer risk hypothesized to identify the frail phenotype.
To investigate the predictive utility of the Braden score on outcomes of inpatients with heart failure (HF).
Retrospective cohort study.
An academic medical center between January 1, 2012 and June 30, 2013.
642 inpatients with a primary diagnosis of HF (ICD-9 428).
The primary predictor was Braden score. Primary outcome was 30-day mortality. Additional outcomes included 30-day readmission, length of stay (LOS), and discharge destination. Multivariable methods were used to determine the association between the primary predictor and each outcome adjusted for patient demographics and clinical variables.
Mean admission and discharge Braden scores were 19.5 ± 2.3 (SD) (range = 9-23) and 20.0 ± 1.9 (range = 11-23), respectively (P < .0001). Mean age was 61.8 ± 16.2 years (range = 19-101). The 30-day mortality rate was 4.4%, 30-day readmission rate was 16.2%, mean LOS was 7.0 ± 8.7 days, and 78.2% were discharged home. After adjustment, higher (better) Braden score was significantly associated with decreased 30-day mortality (discharge Braden AOR 0.81 (95% CI 0.66-0.996)), and decreased average LOS (admission Braden β -0.52 days (P = .0002)). Higher discharge Braden score was significantly associated with discharge to home (AOR 1.66 (95% CI 1.42-1.95)). Braden score was not significantly associated with 30-day readmission.
Braden score is an independent predictor of mortality, LOS, and discharge destination among inpatients with HF. Further exploration of the use of Braden scores to identify inpatients who might benefit from specialized intervention is warranted.
Braden评分是一种用于预测压疮风险的常规评估方法,据推测可识别脆弱表型。
探讨Braden评分对心力衰竭(HF)住院患者预后的预测效用。
回顾性队列研究。
2012年1月1日至2013年6月30日期间的一家学术医疗中心。
642例以HF为主要诊断(国际疾病分类第九版428)的住院患者。
主要预测因素为Braden评分。主要结局为30天死亡率。其他结局包括30天再入院率、住院时间(LOS)和出院去向。采用多变量方法确定主要预测因素与经患者人口统计学和临床变量调整后的各结局之间的关联。
入院时和出院时Braden评分的平均值分别为19.5±2.3(标准差)(范围=9 - 23)和20.0±1.9(范围=11 - 23)(P <.0001)。平均年龄为61.8±16.2岁(范围=19 - 101)。30天死亡率为4.4%,30天再入院率为16.2%,平均住院时间为7.0±8.7天,78.2%的患者出院回家。调整后,较高(较好)的Braden评分与30天死亡率降低显著相关(出院时Braden调整后比值比0.81(95%可信区间0.66 - 0.996)),且与平均住院时间缩短相关(入院时Braden评分β -0.52天(P =.0002))。较高的出院Braden评分与出院回家显著相关(调整后比值比1.66(95%可信区间1.42 - 1.95))。Braden评分与30天再入院率无显著关联。
Braden评分是HF住院患者死亡率、住院时间和出院去向的独立预测因素。有必要进一步探索使用Braden评分来识别可能从专门干预中获益的住院患者。